Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Observational

Long Term Follow Up for CTSN Mitral Valve Repair Studies

NCT03066050 · tracked via the Priya Life Science Canada tracker
Phase
Observational
Started
2017-05-03
Last updated
2025-07-16

Condition(s) studied

Mitral Valve InsufficiencyCoronary Artery Disease

Investigational drug(s) / intervention(s)

MV RepairMV ReplacementCABG

MV Repair: Participants underwent mitral valve repair with annuloplasty and a sub-valvular procedure for severe tethering.

MV Replacement: Participants underwent mitral valve replacement and complete preservation of the sub-valvular apparatus.

CABG: Participants underwent coronary artery bypass grafting

Study summary

This study is a continuation of two previous studies --- the Severe Ischemic Mitral Regurgitation (SMR) Trial (NCT00807040) and the Moderate Ischemic Mitral regurgitation (MMR) Trial (NCT00806988) --- to learn more about patients' health 5-10 years after their mitral valve surgeries. The investigators will collect long-term health information on SMR and MMR trial participants using electronic medical records, patient and/or family input, public records, and healthcare- and vital status-related databases.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Randomized patients in the MMR and SMR trials who were still alive at 2 years after the index cardiac surgical intervention Exclusion Criteria: * Patients participating in the MMR and SMR trials who withdrew consent prior to the 2-year follow-up evaluation

Primary outcome measure(s)

  • Survival — up to 10 years post-surgery (at the time of registry data transfer)
    All-cause mortality will be assessed.

Trial sites (24)

FacilityCityRegionStatus
University of Southern California Los Angeles California
Emory University Atlanta Georgia
University of Maryland Baltimore Maryland
Suburban Hospital Bethesda Maryland
Brigham and Women's Hospital Boston Massachusetts
Columbia University Medical Center New York New York
Montefiore Einstein Heart Center The Bronx New York
Mission Hospital Asheville North Carolina
Duke University Durham North Carolina
East Carolina Heart Institute Greenville North Carolina
Cleveland Clinic Foundation Cleveland Ohio
Ohio State University Columbus Ohio
University of Pennsylvania Philadelphia Pennsylvania
Baylor Research Institute Plano Texas
University of Virginia Health Systems Charlottesville Virginia
Inova Heart and Vascular Institute Falls Church Virginia
University of Alberta Hospital Edmonton Alberta
Sunnybrook Health Science Centre Toronto Ontario
Saint Michael's Hospital Toronto Ontario
Toronto General Hospital Toronto Ontario
Montreal Heart Institute Montreal Quebec
Centre Hospitalier de l'Université de Montréal Montreal Quebec
Hôpital du Sacré-Cœur de Montréal Montreal Quebec
Institut Universitaire de Cardiologie de Quebec (Hopital Laval) Québec Canada

More Icahn School of Medicine at Mount Sinai trials in Canada

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03066050 on ClinicalTrials.gov ↗ ← All trials in Canada